Castle Biosciences (CSTL) Consolidated Net Income (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Consolidated Net Income data on file, last reported at -$14.5 million in Q1 2026.

• Quarterly Consolidated Net Income rose 43.82% year-over-year to -$14.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.8 million (down 153.15% YoY) and the FY2025 annual result came in at -$24.2 million, down 232.41% from the prior year.
• Consolidated Net Income eased to -$14.5 million in Q1 2026 per CSTL's latest filing, from -$2.3 million in the prior quarter.
• The five-year high for Consolidated Net Income was $9.6 million in Q4 2024, with the low at -$29.2 million in Q1 2023.
• Average Consolidated Net Income over 5 years is -$8.5 million, with a median of -$2.6 million recorded in 2023.
• Year-over-year, Consolidated Net Income plunged 1039.38% in 2023 and jumped 471.71% in 2024.
• Castle Biosciences' Consolidated Net Income stood at -$20.6 million in 2022, then surged by 87.49% to -$2.6 million in 2023, then jumped by 471.71% to $9.6 million in 2024, then slumped by 124.32% to -$2.3 million in 2025, then slumped by 522.73% to -$14.5 million in 2026.
• Business Quant data shows CSTL's Consolidated Net Income at -$14.5 million in Q1 2026, -$2.3 million in Q4 2025, and -$501000.0 in Q3 2025.